# About metabolixpeptides > About metabolixpeptides — Mapping the Metabolic-Peptide Literature — About metabolixpeptides: an independent literature digest on three Metabolic & Weight Research peptides — how the site is built, what it covers, and where its coverage stops. **METABOLIC & WEIGHT RESEARCH / COLOPHON** A citation-anchored map of three peptides studied for metabolic regulation, at three very different evidence stages. Nothing sold, no one treated, no advice given. ## What this desk covers metabolixpeptides charts the published research on three peptides connected by one broad theme — **metabolic regulation and weight management** — approached from three structurally distinct directions: a receptor agonist, a hormone fragment, and a mitochondria-encoded signal. Each compound holds its own page; a comparison page lays the three side by side on mechanism, evidence stage, and regulatory status; and one shared references list gathers every source drawn on across the site. A field this crowded, and this often overstated in marketing copy, needs a legible account of what is actually known. Each page states plainly what was studied, in whom, at what stage of development, and how far that evidence honestly reaches — which for these three compounds ranges from a decade of large, FDA-reviewed clinical trials down to mouse studies with no completed human trial at all. Holding that line, compound by compound, is the entire reason this site exists. ## How the map is drawn Every factual claim on this site carries a numbered citation traceable to a peer-reviewed article, a registered clinical-trial publication, or a dedicated safety review, gathered with DOIs and PubMed links on the [references page](/references). Where a finding comes from a large randomized trial in thousands of people, the page says so; where it comes from a mouse study, a small human cohort, or an observational database rather than a controlled trial, the page says that too, explicitly and without softening it. Where a page reports how people describe their own experience with a compound — drawn from patient forums and research-community discussion — that material is always labeled as anecdotal, kept separate from the cited clinical literature, and never attached to a dose. For MOTS-c specifically, where no such community-reported body of experience exists in any substantial or verifiable form, this site says that plainly rather than filling the gap. ## The edges of the map metabolixpeptides is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. Nothing here is sold, sourced, or brokered, and no pharmaceutical company, supplier, or clinic pays for placement on any page. No clinician is on staff; nothing is diagnosed, and no dose, schedule, or route is ever named for any individual person. Semaglutide is an approved prescription medicine, reachable only through a licensed provider. AOD-9604 is a discontinued drug candidate available legally, at present, only within the bounds of research use. MOTS-c is a research chemical with no completed human trial. Anyone seeking clinical guidance about any of these compounds should take that question to a licensed provider in their own jurisdiction. Corrections and citation notes are welcome via the [contact page](/contact); requests for medical advice cannot be answered there. --- A citation-led survey of metabolic-signaling peptides — incretins, fragments, and mitochondrial messengers — read as literature, not as a prescription.